Literature DB >> 33310664

Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients.

Yanan Wang1, Jingjing Li2, Huijun Li3, Ping Lei4, Guanxin Shen4, Chunguang Yang5.   

Abstract

To better understand humoral immunity following SARS-CoV-2 infection, 114 hospitalised COVID-19 patients with antibody monitored over 8 weeks from symptom onset were retrospectively investigated. A total of 445 serum samples were assessed via chemiluminescence immunoassay. Positive rate of virus-specific IgM reached up to over 80% from the second week to the eighth week after symptom onset, then declined quickly to below 30% in the twelfth week. Concentrations of IgG remained high for at least 3 months before subsequently declining. As compared with the non-severe group, serum IgM level from week 3 to week 8 was significantly higher among the patients with severe clinical symptoms (P = 0.012) but not IgG (P = 0.053). Serum IgM level from week 3 to week 8 was correlated with positive virus RNA test (r = 0.201, P = 0.044), albumin level (r = -0.295, P = 0.003), lactic dehydrogenase (LDH) level (r = 0.292, P = 0.003), alkaline phosphatase (ALP) level (r = 0.254, P = 0.010), C-reactive protein (CRP) level (r = 0.281, P = 0.004) during the same course, while serum IgG level was correlated with age (r = 0.207, P = 0.038). This presented results provide insight into duration of SARS-CoV-2 antibodies and interaction between the virus and host systems.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Humoral immunity; Illness severity; Immunoglobulin G; Immunoglobulin M; SARS-CoV-2

Year:  2020        PMID: 33310664     DOI: 10.1016/j.intimp.2020.107271

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test.

Authors:  Mariangela F Silveira; Marilia A Mesenburg; Odir A Dellagostin; Natasha R de Oliveira; Mara Ac Maia; Francisco D Santos; André Vale; Ana M B Menezes; Gabriel D Victora; Cesar G Victora; Aluisio Jd Barros; Luis Paulo Vidaletti; Fernando P Hartwig; Fernando C Barros; Pedro C Hallal; Bernardo L Horta
Journal:  Braz J Infect Dis       Date:  2021-08-05       Impact factor: 3.257

Review 2.  Animal Coronaviruses and SARS-COV-2 in Animals, What Do We Actually Know?

Authors:  Paolo Bonilauri; Gianluca Rugna
Journal:  Life (Basel)       Date:  2021-02-05

3.  SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.

Authors:  Tatsuya Yoshihara; Kazuya Ito; Masayoshi Zaitsu; Eunhee Chung; Izumi Aoyagi; Yoshikazu Kaji; Tomomi Tsuru; Takuma Yonemura; Koji Yamaguchi; Shinichi Nakayama; Yosuke Tanaka; Nobuo Yurino; Hideki Koyanagi; Shunji Matsuki; Ryuji Urae; Shin Irie
Journal:  Int J Environ Res Public Health       Date:  2021-04-05       Impact factor: 3.390

4.  [SARS-CoV-2 IgG seroprevalence in personnel of the extraclinical fight against the COVID-19 pandemic].

Authors:  Bastian Brune; Johannes Korth; Kai Fessmann; Daniel Stappert; André Nohl; Thomas Lembeck; Fabian Standl; Andreas Stang; Ulf Dittmer; Oliver Witzke; Anke Herrmann; Marcel Dudda
Journal:  Notf Rett Med       Date:  2021-10-12       Impact factor: 0.826

5.  Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals.

Authors:  Nuria Tormo; David Navalpotro; María Martínez-Serrano; Marta Moreno; Fernando Grosson; Irene Tur; Maria Remedios Guna; Pepa Soriano; Ana Tornero; Concepción Gimeno
Journal:  Diagn Microbiol Infect Dis       Date:  2021-10-10       Impact factor: 2.983

Review 6.  Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.

Authors:  Jiaxin Zheng; Yingying Deng; Zhenyu Zhao; Binli Mao; Mengji Lu; Yong Lin; Ailong Huang
Journal:  Cell Mol Immunol       Date:  2021-10-13       Impact factor: 11.530

7.  The association between micronutrients and the SARS-CoV-2-specific antibodies in convalescent patients.

Authors:  Maryam Panahibakhsh; Faramarz Amiri; Taher Doroudi; Mostafa Sadeghi; Pirhossein Kolivand; Fatemeh Alipour; Ali Gorji
Journal:  Infection       Date:  2022-02-21       Impact factor: 7.455

8.  Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21.

Authors:  Erik Eik Anda; Tonje Braaten; Kristin Benjaminsen Borch; Therese Haugdahl Nøst; Sairah L F Chen; Marko Lukic; Eiliv Lund; Frode Forland; David A Leon; Brita Askeland Winje; Anne-Marte Bakken Kran; Mette Kalager; Fridtjof Lund Johansen; Torkjel M Sandanger
Journal:  Euro Surveill       Date:  2022-03

9.  Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study.

Authors:  Alexandr Zurochka; Maria Dobrinina; Vladimir Zurochka; Desheng Hu; Alexandr Solovyev; Liana Ryabova; Igor Kritsky; Roman Ibragimov; Alexey Sarapultsev
Journal:  Vaccines (Basel)       Date:  2021-06-09

10.  Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust.

Authors:  David Hodgson; Hayley Colton; Hailey Hornsby; Rebecca Brown; Joanne Mckenzie; Kirsty L Bradley; Cameron James; Benjamin B Lindsey; Sarah Birch; Louise Marsh; Steven Wood; Martin Bayley; Gary Dickson; David C James; Martin J H Nicklin; Jon R Sayers; Domen Zafred; Sarah L Rowland-Jones; Goura Kudesia; Adam Kucharski; Thomas C Darton; Thushan I de Silva; Paul J Collini
Journal:  medRxiv       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.